Allianz Asset Management GmbH Buys 33,894 Shares of ADMA Biologics Inc $ADMA

Allianz Asset Management GmbH boosted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 210.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the biotechnology company’s stock after purchasing an additional 33,894 shares during the quarter. Allianz Asset Management GmbH’s holdings in ADMA Biologics were worth $910,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ADMA. Skandinaviska Enskilda Banken AB publ bought a new position in shares of ADMA Biologics in the first quarter worth about $35,000. SVB Wealth LLC purchased a new stake in ADMA Biologics in the first quarter worth about $35,000. Smartleaf Asset Management LLC lifted its position in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 1,493 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of ADMA Biologics during the second quarter valued at about $46,000. Finally, Toth Financial Advisory Corp lifted its position in shares of ADMA Biologics by 1,081.6% during the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 2,293 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $27.67.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $15.18 on Monday. The firm’s 50 day simple moving average is $15.81 and its 200-day simple moving average is $18.24. ADMA Biologics Inc has a 12 month low of $13.50 and a 12 month high of $25.67. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of 17.65 and a beta of 0.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to analysts’ expectations of $121.77 million. During the same quarter last year, the company earned $0.13 EPS. The firm’s revenue for the quarter was up 13.8% compared to the same quarter last year. Analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.